Arvinas, Inc.
ARVNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Arvinas, Inc. (ARVN) is listed under Biotechnology. Valued at $477.3M, ARVN is a small-cap name in its sector. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Market Cap
$477.3M
Beta
1.81
P/E (TTM)
29.20
P/E (Fwd)
-2.26
EPS (TTM)
$0.25
EPS (Fwd)
$-3.23
ROE
1.6%
ROA
-1.0%
Cash
$567.9M
Total Debt
$8.0M
Free CF
-$94.5M
52W Change
-20.7%
Annual Financials
Cash vs Debt
Where ARVN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ARVN finished 18.70% below its 150-day moving average ($8.93) and 26.52% below its 200-day moving average ($9.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARVN overbought or oversold?
At the October 20, 2026 close, ARVN's RSI(14) was 45.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $567.9M in cash and $8.0M in debt, ARVN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$94.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 1.6% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $131.4M to $262.6M.
Arvinas, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ARVN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.